Immunochemical analyses of estrogen receptors in human breast tumors by a novel monoclonal estrogen receptor antibody (EVG F9).
The objective of this study was to assess the potential utility of a new site-directed, monoclonal anti-estrogen receptor antibody (EVG F9) in detection and analyses of human breast tumor estrogen receptor (ERalpha), using immunoblotting and immunohistochemical assays. Using Western Blot analyses, we demonstrated that EVG F9 monoclonal antibody binds specifically to ERalpha and does not cross-react with ERbeta. Furthermore, binding of EVG F9 to ERalpha was effectively displaced with the immunogenic peptide in Western Blots and in immunohistochemical analyses. In Western Blot analyses, EVG F9 detected ERalpha at low concentrations approaching 5 to 10 fmol/sample. Determination of ERalpha status of a series of human breast tumor samples by Western Blot analyses or immunohistochemistry using EVG F9 correlated well with ERalpha values measured by ligand binding assays. These observations suggest that EVG F9 monoclonal anti-ERalpha antibody is a valuable immunochemical tool for detection and analyses of ERalpha in human breast tumors.
Department of Biochemistry, Boston University School of Medicine, Center for Advanced Biomedical Research, Boston, MA 02118, USA.
N S
NS
Rost
K
K
Murphy
L
L
Hafer
M
M
Pavao
A M
AM
Traish
D000911:Antibodies, Monoclonal; D000918:Antibody Specificity; D001943:Breast Neoplasms / Q000378:metabolism*; D047628:Estrogen Receptor alpha; D005260:Female; D006801:Humans; D015151:Immunoblotting; D007150:Immunohistochemistry / Q000379:methods*; D011960:Receptors, Estrogen / Q000032:analysis* / Q000235:genetics / Q000276:immunology*
D000911:Antibodies, Monoclonal; D047628:Estrogen Receptor alpha; D011960:Receptors, Estrogen